DSIP peptide (emideltide): FDA status, sleep evidence, and the 2026 panel vote

01

DSIP and emideltide naming can hide product differences

DSIP expands to delta sleep-inducing peptide and is commonly used as another name for emideltide. FDA’s July 2026 staff review describes emideltide as a nonapeptide, meaning a chain of nine amino acids. That biochemical description does not establish a medical use, product identity, or finished-drug approval.

FDA evaluated both emideltide free base and emideltide acetate because the withdrawn nomination packages and supporting material did not consistently identify which bulk substance was intended. The agency emphasizes that the free base and acetate are different bulk drug substances. A provider or seller that lists only “DSIP” may therefore leave a basic identity question unresolved.

Product form is not a technical footnote. Reference standards, purity tests, concentration statements, stability, impurities, and biological behavior must be matched to the substance actually used. A certificate for one form cannot automatically authenticate another, and the common name does not prove that a marketed vial matches material from an older study.

02

Current FDA status: no approved drug and no final list change

FDA’s staff briefing says neither emideltide free base nor emideltide acetate has an applicable USP or National Formulary drug-substance monograph and neither is a component of an FDA-approved drug. Staff concluded that the evaluation criteria weighed against adding both forms to the 503A Bulks List.

At the July 24, 2026 Pharmacy Compounding Advisory Committee meeting, the committee considered the substances for proposed uses involving opioid withdrawal, chronic insomnia, and narcolepsy. Contemporary meeting coverage from RAPS and STAT reports that the committee did not recommend emideltide-related substances for list inclusion.

An advisory vote is not a final FDA rule. As of this article’s July 29 review, the vote had not made DSIP FDA-approved, had not placed it on or removed it from the final 503A Bulks List by itself, and had not created a product recall. Current status should be checked on FDA’s live compounding pages because later agency action can change the regulatory record.

03

The human sleep studies are small, old, and mixed

A 1981 controlled study involved six healthy volunteers who received intravenous DSIP and reported changes in short-term and later sleep measures. Its tiny sample, intravenous route, and healthy-volunteer population make it unsuitable as proof for a modern product marketed to people with chronic insomnia.

A 1987 double-blind crossover study in patients with insomnia found some sleep-stage differences, but the authors concluded that the improvement was of little clinical significance. A 1992 matched-pairs study involved 16 patients with chronic insomnia; although some objective measures differed, the authors said the effects were weak, could partly reflect changes in the placebo group, and were unlikely to represent major therapeutic benefit.

Those studies are not interchangeable with a subcutaneous injection or nasal product sold decades later. They do not establish a standardized formulation, long-term safety, comparative benefit, product-quality specification, or effectiveness for withdrawal or narcolepsy. The responsible summary is mixed and limited evidence—not that DSIP is proven to improve sleep and not that it has been disproven for every possible research question.

04

FDA’s safety concern centers on missing information as well as peptide quality

FDA’s current safety-risk page says compounded drugs containing emideltide may pose immunogenicity risk for certain routes and may involve complexities with peptide-related impurities and active-pharmaceutical-ingredient characterization. The agency also says it has not identified safety-related information for the proposed route and lacks enough information to know whether the drug would cause harm in humans.

That is a statement of uncertainty, not a claim that a specific adverse event will occur. It also means a seller should not market absence of reported events as evidence of safety. When exposure is poorly tracked, product identity varies, and systematic trials are limited, a lack of reports cannot establish a reliable event rate.

Potential risk can arise from the peptide, aggregation, immune response, impurities, concentration, sterility, container, storage, or administration. A high purity percentage addresses only the tested sample and method; it cannot substitute for finished-product controls, clinical evidence, a lawful ingredient pathway, or individualized medical oversight.

05

Sleep and withdrawal marketing can overstate what FDA reviewed

The FDA committee reviewed named proposed uses because those uses appeared in the nomination record. Review does not mean FDA accepted the condition, product, route, or benefit claim. A clinic post saying “FDA reviewed DSIP for sleep” can be literally incomplete and materially misleading if it omits that staff recommended against list inclusion and advisers voted unfavorably.

Likewise, a reference to an old intravenous study does not support a nasal spray, subcutaneous vial, oral product, or multi-ingredient stack. Route, formulation, population, comparator, endpoint, and follow-up duration must match before evidence is applied to a marketed product.

Insomnia, narcolepsy, and opioid withdrawal are medical conditions that can require appropriate evaluation and evidence-based care. This guide does not diagnose a sleep disorder, recommend DSIP, or provide a protocol. People with concerning symptoms, substance-withdrawal risks, or an emergency should seek appropriate professional or urgent care.

06

How to research a provider or seller offering DSIP

Ask for the exact chemical name and form, concentration, route, intended use, prescribing clinician, dispensing pharmacy, and current legal basis. If the answer is only “DSIP peptide,” request clarification about emideltide free base versus acetate and how the product label matches the supporting documentation.

Then examine the evidence claim. Identify the actual study, participant count, route, duration, comparator, and outcome. Claims such as “induces deep sleep,” “resets circadian rhythm,” “treats withdrawal,” or “clinically proven” require evidence for the exact product and use; the small older studies do not justify those broad statements.

Finally, check FDA’s current 503A materials, the relevant pharmacy license, the prescriber’s state authority, and whether an injectable is being sold outside a prescription pathway. Do not treat the July advisory process as approval. Treatment questions belong with an appropriately licensed clinician who can discuss established options and individual risks.

• →Emideltide free base or acetate
• →Exact route, concentration, and finished-product source
• →Direct citation for each sleep or withdrawal claim
• →Current FDA list and policy status
• →Prescriber and pharmacy licenses
• →Adverse-event and emergency pathway